The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | The importance of PI3-kinase delta in CLL and NHL
Klaus Okkenhaug, PhD from the Babraham Institute, Cambridge, UK discusses the importance of PI3 kinase, specifically the delta isoform in chronic lymphocytic lymphoma (CLL) and indolent Non-Hodgkin lymphoma (NHL). PI3 kinase delta is selectively expressed in immune cells and is particularly involved in the activation and differentiation of B-cells. It is a target for the drug idelalisib, and works by interfering in the B-cell receptor signaling pathway or signaling downstream of chemokine receptors. However, patients treated with idelalisib have shown adverse effects, commonly colitis. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
